FDA Approves Bemotrizinol, First New Sunscreen Ingredient in Over 25 Years
The FDA approved bemotrizinol, a new sunscreen ingredient that has been used in Europe since 1999, marking the first approval of a novel sunscreen ingredient in the U.S. in more than 25 years. The ingredient protects against both UVA and UVB rays without leaving white streaks like mineral-based sunscreens and will initially be sold under the brand name Parsol Shield by DSM Nutritional Products. The approval represents a significant update to American sunscreen technology and demonstrates the effectiveness of a streamlined approval process authorized by Congress in 2020.
The FDA has approved bemotrizinol as a new sunscreen ingredient for the U.S. market, the first such approval in over 25 years. The ingredient, which has been authorized in Europe since 1999 and was first filed with the FDA in 2005, meets the agency's safety and efficacy standards for protecting against ultraviolet rays while causing minimal skin irritation or absorption. Bemotrizinol is safe for use in adults and children 6 months and older and will initially be marketed by Dutch manufacturer DSM Nutritional Products under the brand name Parsol Shield, with an 18-month exclusivity period before other manufacturers can use it. The ingredient fills a gap in the current U.S. market by providing broad-spectrum UVA and UVB protection without the white residue associated with mineral-based sunscreens, addressing a limitation of existing chemical sunscreen ingredients that typically protect against only one type of UV ray. This approval represents the first ingredient to successfully navigate a streamlined review process authorized by Congress in 2020, potentially accelerating future sunscreen innovations.
What's missing
The articles do not discuss potential pricing implications or how bemotrizinol's cost might compare to existing sunscreen options, nor do they address any remaining safety monitoring or post-market surveillance plans. Additionally, there is limited discussion of why the approval took 18 years from initial FDA filing (2005) to approval despite European authorization since 1999.
How coverage differed
STAT News presented the approval straightforwardly as a regulatory achievement with expert commentary supporting the decision. The framing emphasized the long delay (25+ years, with bemotrizinol filed in 2005) as a bureaucratic problem now solved, which could be seen as implicitly critical of FDA processes, though the reporting remained factual and balanced.
What different sources said
- STAT NewsCenter
FDA OKs first new sunscreen ingredient in more than 25 years
Related
Culturally Adapted Health Program Shows Promise for Rural Latina Women in California
A pilot study from UC Riverside found that a culturally adapted health program called ¡Coma, Muévase y Viva! helped low-income Latina and Indigenous Mexican women in rural Southern California make healthier lifestyle changes. The program was led by promotoras (community health workers) and conducted in 2022. The results suggest culturally tailored interventions may be effective for improving health outcomes in underserved communities.
Study Identifies Brain Circuit Responsible for TMS Antidepressant Effects
Researchers at Weill Cornell Medicine have identified a neural circuit connecting the prefrontal cortex to the insular cortex that appears to mediate the antidepressant effects of transcranial magnetic stimulation (TMS). TMS is a non-invasive brain stimulation technique increasingly used to treat depression when other treatments fail. This discovery could help optimize TMS treatment protocols and improve outcomes for depression patients.
RFK Jr. Appointed as Health Care Affordability Official, Targets Hospital Costs
Robert F. Kennedy Jr. has been appointed to a health care affordability role and is focusing on reducing hospital costs. Kennedy, known for his work on health issues, has a non-traditional work schedule according to reporting. His appointment represents a significant shift in health care policy direction under the new administration.